Turning to the “Infected Jelly” to Treat Ebola

The NEJM has come out with a very interesting paper: Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. The explosive outbreak of Ebola Virus Disease in West Africa last year had hijacked the headlines and media space in a big way. Multiple solutions were touted, including the vaccine trial STRIVE. Few articles, however, looked at the systems response to the crisis. Although the current … Continue reading Turning to the “Infected Jelly” to Treat Ebola

Rate this:

If Carbapenems Go, Can Colistin be Far Behind?

I wrote about the disaster-in-the-making discovery of transmissible resistance to colistin, a last resort antibiotic, when the Lancet Infectious Diseases published a paper based on data coming out from surveillance in China. At that point of time, the isolation of the transmissible gene providing resistance (mcr1 gene) gained a lot of attention. Maryn McKenna’s blog post went viral and there was a lot of tornadoes in Twitter. … Continue reading If Carbapenems Go, Can Colistin be Far Behind?

Rate this:

What's your p-value?

Ronald Fisher and Some Thoughts on the p-Value

One of the most discussed, debated and controversial issues in medical research is the p-value. I came across Ronald Fisher’s take on this matter in his work, Statistical Methods for the Research Worker, 1925 (the text of this work has been made available online by Christopher D. Green of the York University): “The value for which P=0.05, or 1 in 20, is 1.96 or nearly … Continue reading Ronald Fisher and Some Thoughts on the p-Value

Rate this: